Managing a Novel Therapeutic Option for mUC Treatment
A leading medical authority shares their hands-on experience with sacituzumab govitecan, focusing on the primary toxicity concerns, such as diarrhea and neutropenia, and outlining effective management strategies to mitigate these adverse effects and optimize patient care.
Describe your clinical experience with sacituzumabgovitecan - which patients, sequencing with other lines, major toxicity concerns (e.g. diarrhea, neutropenia) and management strategies.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
